Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: A randomized, controlled, and multicenter study

Renal Failure

Volumn 27, Issue 2, 2005, Pages 205-212

  Gu, Y ^a  

^a NONE

Author keywords

Alfacalcidol; iPTH; Secondary hyperparathyroidism

Indexed keywords

ALBUMIN; ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH DISEASE; VOMITING;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PULSE THERAPY, DRUG; RENAL DIALYSIS;

EID: 15344341867     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200049538     Document Type: Article

References (13)

1. Moe, S.M.; Kraus, M.A.; Gassensmith, C.M.; Fineberg, N.S.; Cannon, F.H.; Peacock, M. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol. Dial. Transplant. 1998, 13 (5), 1234-1241.
2. Heaf, J.G.; Lokkegard, H. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age. J. Nephrol. 1998, 11 (4), 203-210.
3. Brandi, L.; Egfjord, M.; Olgaard, K. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uremic men. Nephrol. Dial. Transplant. 2002, 17 (5), 829-842.
4. Gogusev, J.; Duchambon, P.; Hory, B.; et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997, 51 (1), 328-336.
5. Fukagawa, M.; Kazama, J.J.; Shigematsu, T. Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. Nephrol. Dial. Transplant. 2002, 17 (9), 1553-1557.
6. Wang, X.; Sun, B.; Zhou, R; Hu, J.; Yu, X.; Peng, T. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients. Chin. Med. J. (Engl). 2001, 114 (4), 410-414.
7. Ardissino, G.; Schmitt, C.P.; Testa, S.; Claris-Appiani, A.; Mehls, O. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. Pediatr. Nephrol. 2000, 14 (7), 664-668.
8. Herrmann, P.; Ritz, E.; Schmidt-Gayk, H.; et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 1994, 67 (1), 48-53.
9. Norris, K.C. Avoiding the risk of secondary hyperparathyroidsim in chronic renal failure: a new approach, and a review. Dial. Transplant. 2001, 30 (6), 355-367.
10. Jara, A.; Chacon, C.; Valdivieso, A.; Aris, L.; Jalil, R.; Felsenfeld, A.J. Effect of calcitriol treatment and withdrawal on hyperparathyroidism in hemodialysis patients with hypocalcemia. Nephrol. Dial. Transplant. 2001, 16 (5), 1009-1016.
11. Ritzerfeld, M.; Klasser, M.; Mann, H. Alfacalcidol in the therapy of renal bone disease. Int. J. Clin. Pharmacol. Ther. 2001, 39 (12), 546-550.
12. Llach, F.; Yudd, M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am. J. Kidney Dis. 1998, 32 (2 Suppl 2), S3-S12.
13. Norris, K.C. Secondary hyperparathyroidism: defining a model of optimal management. Dial. Transplant. 1999, 28 (11), 630-640.